ArticleEuropean journal of nuclear medicine and molecular imaging2017
Early identification of MCI converting to AD: a FDG PET study.
Article in European journal of nuclear medicine and molecular imaging, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Diagnostic performance of molecular imaging methods in predicting the progression from mild cognitive impairment to dementia: an updated systematic review.European journal of nuclear medicine and molecular imaging · 2024Pooled it
- 18F-FDG PET for Prediction of Conversion to Alzheimer's Disease Dementia in People with Mild Cognitive Impairment: An Updated Systematic Review of Test Accuracy.Journal of Alzheimer's disease : JAD · 2018Pooled it
- Odd-Chain Fatty Acids-Enriched Algal Oil Improves Locomotor Function and Modulates Metabolic Pathways inMolecules (Basel, Switzerland) · 2026Article
- Mapping brain changes in post-COVID-19 cognitive decline via FDG PET hypometabolism and EEG slowing.Scientific reports · 2025Article
- Dissecting the clinical and pathological prognosis of MCI patients who reverted to normal cognition: a longitudinal study.BMC medicine · 2025Article
- Suppressing DUSP16 overexpression induced by ELK1 promotes neural progenitor cell differentiation in mouse models of Alzheimer's disease.Aging cell · 2025Article
- Alzheimer's disease recognition via long-range state space model using multi-modal brain images.Frontiers in neuroscience · 2025Article
- Comparison of Radiomics and conventional SUVr methods for Alzheimer's disease classification using AV45 PET imaging.Frontiers in neurology · 2025Article
- Regional changes in brain metabolism during the progression of mild cognitive impairment: a longitudinal study based on radiomics.EJNMMI reports · 2024Article
- Evaluation of Neurodegenerative Disorders with Amyloid-β, Tau, and Dopaminergic PET Imaging: Interpretation Pitfalls.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Review
- Metabolomics profiling reveals distinct, sex-specific signatures in serum and brain metabolomes in mouse models of Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Evaluation of the Therapeutical Effect of Matricaria Chamomilla Extract vs. Galantamine on Animal Model Memory and Behavior Using 18F-FDG PET/MRI.Current issues in molecular biology · 2024Article
- The use of individual-based FDG-PET volume of interest in predicting conversion from mild cognitive impairment to dementia.BMC medical imaging · 2024Article
- A novel spatiotemporal graph convolutional network framework for functional connectivity biomarkers identification of Alzheimer's disease.Alzheimer's research & therapy · 2024Article
- Comparison ofEJNMMI research · 2024Article
- Metabolomics profiling reveals distinct, sex-specific signatures in the serum and brain metabolomes in the mouse models of Alzheimer's disease.bioRxiv : the preprint server for biology · 2023Article
- Prognostic value of imaging-based ATN profiles in a memory clinic cohort.European journal of nuclear medicine and molecular imaging · 2023Article
- Metabolomic and lipidomic signatures in autosomal dominant and late-onset Alzheimer's disease brains.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023Article
- Molecular insights into sex-specific metabolic alterations in Alzheimer's mouse brain using multi-omics approach.Alzheimer's research & therapy · 2023Article
- Metabolic syndrome and adiposity: Risk factors for decreased myelin in cognitively healthy adults.Cerebral circulation - cognition and behavior · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeMild cognitive impairment (MCI) is a transitional pathological stage between normal ageing (NA) and Alzheimer's disease (AD). Although subjects with MCI show a decline at different rates, some individuals remain stable or even show an improvement in their cognitive level after some years. We assessed the accuracy of FDG PET in discriminating MCI patients who converted to AD from those who did not.
methodsFDG PET was performed in 42 NA subjects, 27 MCI patients who had not converted to AD at 5 years (nc-MCI; mean follow-up time 7.5 ± 1.5 years), and 95 MCI patients who converted to AD within 5 years (MCI-AD; mean conversion time 1.8 ± 1.1 years). Relative FDG uptake values in 26 meta-volumes of interest were submitted to ANCOVA and support vector machine analyses to evaluate regional differences and discrimination accuracy.
resultsThe MCI-AD group showed significantly lower FDG uptake values in the temporoparietal cortex than the other two groups. FDG uptake values in the nc-MCI group were similar to those in the NA group. Support vector machine analysis discriminated nc-MCI from MCI-AD patients with an accuracy of 89% (AUC 0.91), correctly detecting 93% of the nc-MCI patients.
conclusionIn MCI patients not converting to AD within a minimum follow-up time of 5 years and MCI patients converting within 5 years, baseline FDG PET and volume-based analysis identified those who converted with an accuracy of 89%. However, further analysis is needed in patients with amnestic MCI who convert to a dementia other than AD.
Indexed as
Identifiers
28664464What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.